Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.…
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
Outlook Therapeutics (NASDAQ: OTLK) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 17 employees.
The shares were at 0.3900 USD on 20 November 2026, down 66.9% over 52 weeks. Its 52-week range is 0.1610 USD to 2.538 USD: the price is 84.6% below the high and 142.2% above the low.
Its market capitalisation is 94.94M USD.
Outlook Therapeutics reports return on equity of 193.9% and revenue down 99.4% year over year.
Its debt exceeds its cash by 7.19M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 18 December 2026.